Nurix therapeutics announces partial clinical hold for nx-2127 phase 1 trial

San francisco, nov. 01, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that the u.s. food and drug administration (fda) has placed a partial clinical hold on u.s. phase 1 nx-2127-001 study evaluating nx-2127 in various b-cell malignancies. screening and enrollment of new study participants has been paused.
NRIX Ratings Summary
NRIX Quant Ranking